Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 11/20 | 0.52 |
| ▸ | PPARG | P37231 | 9/20 | 0.52 |
| ▸ | PPARA | Q07869 | 8/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10220584 | 0.88 | PPARD (0.69) | PPARDPPARGPPARAHRH3RAB9A | |
| SCHEMBL10219481 | 0.86 | PPARD (0.51) | PPARDPPARGPPARAHRH3RAB9A | |
| SCHEMBL10219580 | 0.85 | PPARD (0.57) | PPARDPPARGPPARAHRH3RAB9A | |
| SCHEMBL10219941 | 0.85 | PPARD (0.72) | PPARDPPARGPPARAHRH3RAB9A | |
| SCHEMBL10220257 | 0.84 | PPARD (0.56) | PPARDPPARGPPARARAB9A | |
| SCHEMBL10220581 | 0.84 | PPARD (0.73) | PPARDPPARGPPARARAB9ANPC1 | |
| SCHEMBL10219981 | 0.83 | PPARD (0.59) | PPARDPPARGPPARA | |
| SCHEMBL10220098 | 0.83 | PPARD (0.48) | PPARDPPARGPPARARAB9ANPC1 | |
| SCHEMBL10219988 | 0.82 | PPARD (0.48) | PPARDPPARGPPARA | |
| SCHEMBL10219985 | 0.81 | PPARD (0.47) | PPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097610-B2 | Derivative having PPAR agonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286974-A1 | Derivative having ppar agonistic activity | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286974-A1 | Derivative having ppar agonistic activity | PPARD, PPARA, PPARG | PPARD 1/4885PPARG 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.